DCM
APLS

Driehaus Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Driehaus Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-75,000
Closed -$372K – 404
2019
Q4 		$372K Buy
+75,000
New +$2.08M 0.01% 434

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Driehaus Capital Management's APLS Position: Q2 2024 in Review

Driehaus Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 503,039 shares — an estimated $29.6M sold.

Driehaus Capital Management first reported a position in APLS in Q3 2019 and held it in 19 quarters. The position peaked at $58.6M in Q3 2022. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Driehaus Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 503,039 Apellis Pharmaceuticals shares in Q2 2024, an estimated $29.6M.
  • Driehaus Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 19 quarters.
  • Driehaus Capital Management's Apellis Pharmaceuticals position peaked at $58.6M in Q3 2022.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Driehaus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.